Fenofibrate and metabolic syndrome.
The fibric acid derivative, fenofibrate (FF) has been used in the US since 1998 to manage patients with dyslipidemia. Typical changes in serum lipids as result a of FF treatment include clinically important mean reductions of serum triglycerides (TG) by a mean change of -93.7 mg/dL (-39.3%), increases of high density lipoprotein cholesterol (HDLC) by +5.5 mg/dL (+12.4%), and reductions in low density lipoprotein cholesterol (LDLC) by -17.9 mg/dL (-12.3%). The greatest reductions in serum TG are usually observed in subjects with elevated baseline TGs including those with the metabolic syndrome (MetS). Although statins remain the mainstay of therapy for most dyslipidemic patients, their combined use with FF would be expected to address residual risk resulting from less than optimal TG and HDLC levels in such patients. Clinical trials examining the cardiovascular benefits of FF alone or combined with statins have produced mixed results. These observations underscore our lack of understanding of which patients may benefit from FF therapy and which do not. Although FF's basic mechanism of action is known to involve PPAR-alpha agonist activity resulting in altered transcription of several genes, the actual genetic bases for variability in lipid response is poorly understood. Studies, such as our GOLDN study and others designed to better understand the genetic determinants of variability in the response to FF treatment and lipid levels. As a result several important genetic determinants of lipid levels have been identified. For example, in the GOLDN study SNPs from different genes were significantly associated with baseline lipid levels before treatment (APOA5- rs662799, rs3135506; APOC3- rs5128, rs2854117, rs4520); APOA4- rs5104; PPARA- rs9626730, rs135543, rs11703495; LPL- rs1801177), after treatment PPARA- rs11708495; LPL- rs1801177, and appeared to modulate overall response to FF treatment (NOS3- rs1799983). In this article, we will review the literature leading up to the contemporary use of FF as an agent to manage patients with dyslipidemia and focus on emerging understanding of the genetic variability in response to FF treatment. On the basis of the available evidence, we conclude that FF is of benefit in the treatment of dyslipidemia, especially among those with MetS. However, more work is needed to specifically identify which individuals derive a benefit from FF administration in terms of clinical outcomes and which do not - particularly in the context of type 2 diabetes.
Kraja
Aldi T
AT
Division of Statistical Genomics, Washington University School of Medicine, 4444 Forest Park Ave., Campus Box 8506, St. Louis, MO 63110, USA. aldi@wustl.edu
Province
Michael A
MA
Straka
Robert J
RJ
Ordovas
Jose M
JM
Borecki
Ingrid B
IB
Arnett
Donna K
DK
D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D015228:Hypertriglyceridemia / Q000097:blood; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000188:drug therapy*; D047493:PPAR alpha / Q000819:agonists; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids; D047493:PPAR alpha; D014280:Triglycerides; D011345:Fenofibrate
Eur Heart J. 2005 May;26(9):897-905
15781429
Am J Cardiol. 2005 Jan 1;95(1):120-2
15619408
Diabetes Care. 2007 Aug;30(8):1945-51
17483155
Circulation. 1998 May 12;97(18):1837-47
9603539
Arch Intern Med. 2002 Dec 9-23;162(22):2597-604
12456232
Am Heart J. 2007 Feb;153(2):335.e1-8
17239698
Prog Clin Biol Res. 1979;32:711-29
523491
Am J Cardiol. 2006 Apr 17;97(8A):89C-94C
16581336
Int J Clin Pharmacol Ther. 2006 Feb;44(2):64-70
16502765
Diabetes Care. 2009 Mar;32(3):493-8
18984774
Cell Mol Life Sci. 2004 Feb;61(4):393-416
14999402
Curr Opin Lipidol. 2009 Dec;20(6):505-11
19829109
EMBO J. 1992 Feb;11(2):433-9
1537328
Clin Pharmacol Ther. 2003 Sep;74(3):236-44
12966367
Circulation. 2004 Sep 7;110(10):1245-50
15326067
Diabetologia. 2007 Oct;50(10):2067-75
17653691
Pharmacotherapy. 2007 Mar;27(3):412-24
17316152
Diabetes Obes Metab. 2008 Jun;10(6):476-83
17459096
Atherosclerosis. 2007 May;192(1):204-10
16781717
Arch Intern Med. 2006 Apr 10;166(7):743-8
16606810
J Am Coll Cardiol. 2008 Jan 29;51(4):459-65
18222357
Clin Drug Investig. 2008;28(10):625-34
18783301
Diabetes Care. 2002 Mar;25(3):627-8
11874962
Proc Natl Acad Sci U S A. 1986 Mar;83(6):1747-51
3456610
Manag Care Interface. 2000 Mar;13(3):52-8
11066277
Diabetes Care. 2005 Jul;28(7):1769-78
15983333
Clin Ther. 2004 Oct;26(10):1599-607
15598476
Endocr Metab Immune Disord Drug Targets. 2010 Jun;10(2):109-23
20384572
Diabetes Care. 2008 Jul;31(7):1405-9
18375418
J Mol Cell Cardiol. 2004 Feb;36(2):295-304
14871557
N Engl J Med. 2010 Apr 29;362(17):1563-74
20228404
Clin Cardiol. 2006 Jun;29(6):268-73
16796078
Am J Med. 1987 Nov 27;83(5B):9-20
3318457
Drugs Aging. 2001;18(9):665-83
11599634
J Cardiovasc Pharmacol. 2003 Jan;41(1):60-7
12500022
Clin Ther. 2004 Sep;26(9):1456-69
15531008
Eur J Hum Genet. 2008 May;16(5):603-13
18212815
Diabetes Care. 2008 May;31(5):910-5
18285551
Science. 2001 Oct 5;294(5540):169-73
11588264
Lancet. 1984 Sep 15;2(8403):600-4
6147641
J Hum Genet. 2008;53(8):709-717
18542840
Atherosclerosis. 2003 Oct;170(2):315-23
14612213
Drugs. 2007;67(1):121-53
17209672
Ann Med. 1991 Apr;23(2):155-9
2069792
Arterioscler Thromb. 1992 Mar;12(3):286-94
1547188
N Engl J Med. 1999 Aug 5;341(6):410-8
10438259
J Am Coll Cardiol. 2005 Jan 18;45(2):185-97
15653014
Mol Cell Biol. 1995 Jun;15(6):3012-22
7539101
Lancet. 2005 Nov 26;366(9500):1849-61
16310551
Hum Genet. 2004 Nov;115(6):468-74
15375693
Lancet. 2005 Oct 8;366(9493):1267-78
16214597
BMC Med Genet. 2009 May 09;10:39
19426517
Biochim Biophys Acta. 1996 Jul 26;1302(2):93-109
8695669
Eur Heart J. 2010 Jan;31(1):92-9
19797259
Drugs. 2004;64(11):1181-96
15161326
Atherosclerosis. 2007 Dec;195(2):385-91
17109866
Metabolism. 2007 Nov;56(11):1534-41
17950105
Atherosclerosis. 2002 Jun;162(2):363-71
11996956
J Clin Invest. 1995 Feb;95(2):705-12
7860752
Ann Med. 2006;38(7):522-8
17101543
Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1417-25
17431185
Toxicol Lett. 1998 Sep 1;98(1-2):13-23
9776557
Am Heart J. 2008 Mar;155(3):499.e9-16
18294485
Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):717-26
12006382
Drugs. 1990 Aug;40(2):260-90
2226216
Circulation. 2004 Jun 15;109(23 Suppl 1):III50-7
15198967
J Lipid Res. 2004 Nov;45(11):2096-105
15342688
Thromb Haemost. 2005 Jul;94(1):193-9
16113803
Am J Med. 1987 Nov 27;83(5B):21-5
3318449
Diabetes Res Clin Pract. 2003 Jul;61 Suppl 1:S27-34
12880692
FEBS Lett. 1992 Aug 31;309(1):37-40
1324848
Atherosclerosis. 2007 Oct;194(2):e123-30
17145061
Vasc Health Risk Manag. 2005;1(3):209-15
17319106
N Engl J Med. 2010 Apr 22;362(16):1477-90
20228403
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):658-63
14751809
Metabolism. 1965 Sep;14:966-75
14327273
J Lipid Res. 2006 Jul;47(7):1339-51
16585781
Expert Opin Pharmacother. 2006 Sep;7(13):1701-14
16925498
Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2160-4
8384714
Endocr Metab Immune Disord Drug Targets. 2008 Sep;8(3):198-207
18782016
JAMA. 2001 May 16;285(19):2486-97
11368702
Clin Chem. 2006 Nov;52(11):2036-42
16990410
Hypertension. 2007 Jun;49(6):1285-90
17404185
Endocr Metab Immune Disord Drug Targets. 2010 Jun;10(2):124-37
20088815
Lancet. 2007 Nov 17;370(9600):1687-97
17988728
Curr Opin Lipidol. 2006 Dec;17(6):653-8
17095910
Am J Epidemiol. 1996 Jun 15;143(12):1219-28
8651220
Biometrics. 1997 Sep;53(3):983-97
9333350
Am J Cardiol. 2005 Feb 15;95(4):462-8
15695129
Ann Pharmacother. 1999 Oct;33(10):1083-103
10534222
J Atheroscler Res. 1963 Sep-Dec;3:427-44
14100884
Genomics. 2007 Dec;90(6):674-9
17936576
Circulation. 2005 Oct 25;112(17):2735-52
16157765
Curr Opin Cardiol. 2009 Jul;24(4):372-9
19424060
Cardiology. 2004;102(2):61-6
15103174
Metab Syndr Relat Disord. 2007 Dec;5(4):305-14
18370800
Obes Res. 2005 Nov;13(11):1885-90
16339118
Cardiovasc Diabetol. 2005 Aug 22;4:13
16111499
Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):395-9
10634964
Endocr Metab Immune Disord Drug Targets. 2010 Jun;10(2):86-108
20406164
Curr Pharm Des. 2009;15(5):537-52
19199980
Curr Med Res Opin. 2004;20(2):241-7
15006019
Nat Genet. 2008 Feb;40(2):161-9
18193043
Pharmacogenet Genomics. 2005 May;15(5):287-93
15864129
Expert Opin Drug Saf. 2006 Jan;5(1):145-56
16370963
Cardiovasc Res. 2007 Jul 15;75(2):398-407
17412316